Publication details
Detekce minimální residuální choroby ze séra pacientů s mnohočetným myelomem
| Title in English | Detection of minimal residual disease from serum in patients with multiple myeloma |
|---|---|
| Authors | |
| Year of publication | 2015 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Detection of minimal residual disease (MRD) is in multiple myeloma (MM) possibly using a specific allele (ASO) real-time quantitative PCR (qPCR), or droplet-digital PCR (ddPCR), based on the detection of specific alterations of the gene for the heavy chain immunoglobulin (IGH) from clonal plasma cells (PC). This approach is burdensome to patients, since they require periodic sampling bone marrow (BM). It has been demonstrated that tumor-derived free circulating DNA (cfDNA) from serum of the peripheral blood (PB) can be used to monitor tumor burden and response to treatment in patients with malignancies. CfDNA thus have the potential to become a non-invasive marker for MM. Aim: The aim of this study was to focus on the possible use of cfDNA to monitor MRD in patients with MM. |